(PRWEB) September 19, 2012
Gould Partners Announces Recommendation to Buy Shares of Pazoo.
Pazoo is an exclusive provider of health and wellness products for humans and pets. They just recently went public over the counter and trade at a compelling $0.390 per share at the time of this writing - a 150%+ return to date. Fortunately, the firm looks nowhere close to hitting its peak, as evidenced by how liquidity has picked up over the last month. Yesterday, volume gained 40% as shares rose from greater awareness over the underlying fundamentals.
By offering the #1 social community for people and their pets, Pazoo has carved out a niche market that is gearing up for large returns in a country where 62% of households have pets. According to the CEO, "[Pazoo] ha[s] only scratched the surface". What makes Pazoo attractive going forward is that it is a potential takeover target for other firms in areas of cross-over value.
Demand has been so high in the industry that major pharmaceutical giant Pfizer is preparing to do an IPO for its animal health business. The business will be called "Zoetis" based on the root "zo", which denotes "animal", found in words like "zoology" and "zoo". This entity is intended to be a standalone unit by July 2013 and is expected to be valued somewhere between $15 billion and $18 billion. Since Pazoo has already built the foundation of a major social network in the industry, speculation of a buyout could send shares higher. Although Pfizer may never end up buying Pazoo, that is besides the point: the idea that Pazoo could be worth more to a suitor ought to be at least partially factored into the stock. When the market corrects for this, just some of the value potential will be unlocked.
But recent news announcements are also likely to provide solid returns in the days ahead. Pet Life, New England's largest chain of pet stores, recently agreed to carry Pazoo's PetMax product line. PetMax H20 Energizer is a major catalyst that will be introduced to this outlet. This product increases oxygen levels in the blood of animals - a practice that has a long history of successfully improving quality of life for children and adults. Direct Response Programs will help the company boost revenue as business flows from the brick-and-mortar store to the Internet and back.
The company also recently gained admission on the Berlin and Munich Stock exchanges. Why does this matter to new retail investors? Well, the company is having meetings in Germany for the week between October 22nd to October 26th. Management will be meeting with investment professionals in major financial centers - a process that will not only gain new leads and partners but also potentially some big-dollar investors.
From the stronger press coverage to the growing demand both from the takeover side and consumer side, Pazoo is well positioned to outperform broader indices. Not coincidentally, the company has reported "dramatic increases" in web traffic. Current daily traffic suggest a 1,000% gain in unique visitors in September over August. This growth has attracted new investors and is being complemented by 70,000 local TV spots in this month alone. Accordingly, Gould Partners strongly recommends buying shares to capitalize on this emerging growth story.
Disclaimer: The distributor of this research report, Gould Partners, is not a licensed investment adviser or broker dealer. We are a consultant to a third-party representing Pazoo and have received one thousand dollars for independent research. Investors are cautioned to perform their own due diligence as information contained within this report has been derived from public sources and cannot be guaranteed by us to be fully accurate. Always discuss investments with a licensed professional before making any financial decision. Statements made herein are often "forward-looking statements" as defined under Section 27A of the Securities Act of 1933, Section 21E of the Securities Act of 1934, and the Private Securities Litigation Reform Act of 1995. Since these statements are uncertain, actual results may be materially different from those expected.